Mucocutaneous Leishmaniasis

0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Knight Therapeutics
Knight TherapeuticsQC - Montréal
2 programs
MiltefosineN/A1 trial
MiltefosineN/A1 trial
Active Trials
NCT02431429Completed55Est. Mar 2019
NCT02429518Completed42Est. Mar 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Knight TherapeuticsMiltefosine
Knight TherapeuticsMiltefosine

Clinical Trials (2)

Total enrollment: 97 patients across 2 trials

Dedicated QT Study in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis

Start: Dec 2015Est. completion: Mar 201842 patients
N/ACompleted

Spermiogram Assessment in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis

Start: Jul 2015Est. completion: Mar 201955 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space